Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
Status:
Recruiting
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
The goal of this prospective, multicenter, single-arm clinical study is to evaluate the
efficacy and safety of toripalimab in combination with axitinib for postoperative adjuvant
therapy for non-clear renal cell carcinoma with high-risk recurrence factors.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School